Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2016 October ; 25(10): 1418–1425. doi:
10.1158/1055-9965.EPI-16-0312.

Metformin, diabetes, and survival among US veterans with colorectal cancer

Jessica K. Paulus¹, Christina D. Williams^{2,3}, Furha I. Cossor⁴, Michael J. Kelley^{2,3}, and Robert E. Martell⁴

¹ Predictive Analytics and Comparative Effectiveness (PACE) Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts

² Division of Hematology-Oncology, Durham VA Medical Center

³ Division of Medical Oncology, Department of Medicine, Duke University

⁴ Division of Hematology-Oncology, Tufts Medical Center

Abstract

Background—Metformin has been associated with improved CRC survival, but investigations are limited by small numbers of patients and confounding by diabetic severity. We examined the association between metformin use and overall survival (OS) in patients with diabetes and CRC in a large population of U.S. veterans, while adjusting for measures of diabetic severity.

Methods—Patients diagnosed with CRC from 1/2001-12/2008 were identified from the Veterans Affairs Central Cancer Registry. Multivariable models were used to examine the adjusted association of OS with diabetes and use of anti-diabetic medications.

Results—21352 patients diagnosed with CRC were identified (n=16355 non-diabetic patients, n=2038 diabetic patients on metformin, n=2136 diabetic patients on medications other than metformin, n=823 diabetic patients not on anti-diabetic medication). Diabetic patients had a significantly worse OS than non-diabetic patients, but metformin users had only a 10% increase in death (HR_{adj} 1.10; 95% CI 1.03-1.17, p=0.004), as compared to 22% for users of other anti-diabetic medications (HR_{adj} 1.22; 95% CI 1.15-1.29, p<0.0001). Among CRC patients with diabetes, metformin users had a 13% improved OS versus patients taking other anti-diabetic medications (HR_{adj} 0.87; 95% CI 0.79-0.95, p=0.003), while diabetic patients not on any anti-diabetic medications did not differ with respect to OS (HR_{adj} 1.02; 95% CI 0.90-1.15, p=0.76).

Conclusion—Among diabetics with CRC, metformin use is associated with improved survival, despite adjustments for diabetes severity and other risk factors.

Impact—These data lend further support to the conduct of randomized studies of possible anti-cancer effects of metformin among patients with CRC.

Corresponding author: Jessica K. Paulus, ScD, Predictive Analytics and Comparative Effectiveness (PACE) Center, Institute of Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center, 800 Washington Street, Box 63, Boston, MA 02111, Phone: 617-636-7792, Fax: 617-636-5560, jpaulus@tuftsmedicalcenter.org.

Conflicts of Interest: No potential conflicts of interest were disclosed.

Presentation: An earlier version of these data was presented as a Poster Highlights Session at the 2014 ASCO Annual Meeting in Chicago, IL.

Keywords

colorectal cancer; metformin; diabetes; cancer survival; prognosis

INTRODUCTION

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men and women worldwide, and the fourth most common cause of cancer death (1,2). Diabetes has also become a major global health challenge (3), and there are epidemiological and biological data linking these two diseases. In several large population studies, an increased risk of cancer – including CRC – has been observed in patients with diabetes or abnormal glucose metabolism (4–9). A metabolic component of CRC prognosis is supported by observations that low dietary glycemic load, physical activity, and HgA1c < 7.5% are associated with improved CRC survival (10–13).

In light of these data, the possible role of diabetic therapies in cancer initiation and progression has garnered significant attention. Evidence from in vitro and in vivo studies suggests that the diabetic therapy metformin may also have anti-cancer activity via effects on blood insulin and glucose, cancer cell proliferation and apoptosis, and cancer stem cell growth by activating the adenosine monophosphate-activated protein kinase (AMPK)/liver kinase B-1 (LKB1) pathway, inhibiting the mammalian target of rapamycin (mTOR), and lowering insulin-like growth factor-1 (IGF-1) levels (14–17).

In epidemiologic investigations, use of metformin has been associated with lower cancer incidence in diabetic populations (18–20). In a meta-analysis including nearly 850000 individuals with diabetes, metformin use as compared to non-use was associated with an 11% reduced risk of colorectal cancer (21). A number of epidemiologic investigations have found that metformin use is also associated with improved CRC outcomes (22–25). A meta-analysis of six epidemiologic studies including roughly 2400 diabetic patients with CRC reported a reduction in risk of overall- and CRC-specific mortality of 44% and 34%, respectively, among ever-users of metformin (26). However, significant heterogeneity between studies was observed and not fully explored. Moreover, existing individual studies are limited by small numbers of patients with both diabetes and CRC, and lack information on diabetes severity, which is critical to account for potential confounding by indication, given known associations between diabetes and survival.

To address the challenges of sample size and potential confounding by indication, we examined the associations between diabetes, metformin use, and overall survival in the Veterans Affairs (VA) Central Cancer Registry, which features information on diabetic severity and other predictors of CRC mortality, and includes nearly 5000 patients with both CRC and diabetes.

MATERIALS AND METHODS

Study population and data sources

This population-based retrospective study included patients diagnosed with colorectal cancer (CRC) between January 1, 2001 and December 31, 2008. Data for this study were obtained from the national Veterans Affairs (VA) Central Cancer Registry (VACCR) and the VA Corporate Data Warehouse (CDW). The VACCR contains all patients diagnosed with or treated for cancer in the VA(27) and was used to identify the cohort of patients diagnosed with CRC between 2001 and 2008 and provide data regarding patient demographics and characteristics, tumor characteristics, and primary treatment. Registry data were linked using scrambled social security numbers to several databases in the CDW, which was used to obtain pharmacy, diagnostic, laboratory, and vital status data. This study was approved by the Durham VA Institutional Review Board.

Assessment of Type II Diabetes Mellitus

The primary exposures were diagnosis of type II diabetes mellitus and, among those with diabetes, administration of anti-diabetes medication. Patients were defined as having type II diabetes mellitus based on having an appropriate ICD-9 code (250.x0 or 250.x2) between 6 and 15 months prior to the CRC diagnosis. This interval was chosen to identify patients likely to have a pre-existing diabetes diagnosis. If patients had no diabetes care for more than a year (ie >15 months), then the relevance of the diagnosis may be questioned; if it was simultaneous (ie <6 months) with the diagnosis of CRC, then we would question the pre-existing nature. Pharmacy data from the Decision Support System databases were used to identify patients receiving anti-diabetic medication, including the drug name and date of dispensation. Anti-diabetic medication use was defined as at least two fills within the 6 months before and after CRC diagnosis. We used a four-level categorical variable that classified patients as non-diabetic, diabetic with metformin use, diabetic with non-metformin use, and diabetic with no treatment.

Overall survival

The primary outcome was overall survival, based on death from any cause. Mortality was determined by the date of death in the VA Vital status file, which incorporates information from the VA, Medicare, and the Social Security Administration.(28) Patient information was assessed from the diagnosis date until death or through December 31, 2014 (censor date).

Assessment of potential confounders

Clinical and demographic covariates assessed included patients' age at diagnosis, race (White, Black, Other, Unknown), American Joint Committee on Cancer stage (29) at diagnosis (I, II, III, IV), body mass index (underweight (<18.5 kg/m²), normal weight (18.5-24.9 kg/m²), overweight (25.0-29.9 kg/m²), obese (≥ 30 kg/m²), missing), smoking status (never, current, former, missing), comorbidity, CRC treatment, primary site (colon—including colon, cecum, and rectosigmoid junction vs. rectum) and hemoglobin A1c (HbA1c) and creatinine levels, providing surrogate information on diabetes severity. Comorbidity information was evaluated according to the Charlson comorbidity index (30)

and we assessed diagnosis of each condition documented within 15 months prior to the CRC diagnosis date. To examine comorbidity burden, patients were further classified based on whether their comorbidity index was 0, 1-3, or greater than or equal to 4. Cardiovascular disease was specifically defined as diagnoses of coronary heart disease, stroke/cerebrovascular disease, hypertension, or heart failure. The VA laboratory database was used to obtain HgA1c and creatinine values closest to the CRC diagnosis date, up to 6 months after diagnosis. Primary cancer treatment was obtained from the VACCR and defined as treatment (none, surgery only, surgery + radiotherapy (RT), surgery + chemotherapy (CT), surgery + RT + CT, RT only, CT only, and CT + RT) within 4 months before to 6 months after CRC diagnosis.

Statistical analysis

Demographic and treatment characteristics of colorectal cancer cases were summarized using medians (with interquartile ranges), frequencies, and proportions, by diabetes and diabetes treatment status. Cox proportional-hazards modeling was used to estimate hazard ratios (HR) and their corresponding 95% confidence intervals for the associations between diabetes status, diabetes treatment, and overall survival. Multivariable models were developed based on *a priori* selection of possible confounders using clinical expertise and literature review to identify factors associated with CRC survival and likelihood of diabetic treatment regimen. Age, race, stage, smoking status, BMI, Charlson comorbidity index, and CRC treatment were included in all models, and HgA1c and creatinine were included in models of patients with diabetes. Stratified analyses were designated *a priori* based on plausible modifiers of the association between diabetes therapy and survival, and included stratification by BMI (normal weight, overweight/obese), primary cancer site (colon vs. rectum) and AJCC cancer stage (I, II, III, IV). The statistical significance of effect modification was tested by creating a cross product term between the stratification variable and diabetes therapy. Survival curves were obtained using the Kaplan-Meier method. All significance tests were two-sided and p-values less than 0.05 were considered statistically significant. Analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC).

RESULTS

Cohort clinical and demographic characteristics

The predominantly male (98%) study population included 16309 non-diabetic and 4983 diabetic CRC cases identified from the VACCR who were diagnosed with CRC between 2001 and 2008. Among the diabetic patients, there were 2033 metformin users, 2132 users of other diabetic medications, and 818 diabetic patients with no diabetic treatment within the 6 months before and after the date of CRC diagnosis. The median age at colorectal cancer diagnosis was 68.6, 67.9, 73.3 and 72.6 years for non-diabetic cases, metformin users, users of other diabetic medications, and those with no diabetic treatment, respectively (**Table 1**). Metformin users were more likely to be of white race, and to have fewer comorbidities than the other two cohorts of diabetic patients. The median HgA1c level for metformin users was 6.9%, compared to 6.8% for users of other diabetic medications and 6.2% for those with no diabetic medication use.

Diabetes status, diabetes treatments, and overall survival among CRC patients

In crude analysis, diabetic patients using treatments other than metformin or no diabetic treatment had a statistically significantly worse overall survival compared to non-diabetic patients ($p<0.0001$ for both comparisons). However, patients using metformin did not have a significantly different survival rate than non-diabetics ($p=0.09$) (Kaplan Meier curves presented in **Supplementary Figure 1**, global log rank $p<0.0001$). After adjustment for age, race, smoking status, AJCC cancer stage, BMI, comorbidity index, and CRC treatment, diabetics using metformin ($HR_{adj}=1.10$, 95% CI 1.03-1.17, $p=0.004$) and diabetics using other medications ($HR_{adj}=1.22$, 95% CI 1.15-1.29, $p<0.0001$) had a statistically significantly worse overall survival compared to non-diabetics (**Table 2**). Among the 4983 colorectal cancer patients with diabetes, metformin users had a significant 13% reduction in mortality compared to users of other diabetic medications ($HR_{adj}=0.87$, 95% CI 0.79-0.95, $p=0.003$), after adjustment for HgA1c and creatinine, as well as age, race, smoking status, AJCC cancer stage, BMI, comorbidity index, and CRC treatment. Diabetics not using diabetic medications did not have a significantly different survival than diabetic users of other diabetic medications ($p=0.76$).

Diabetes, diabetes treatments, and OS: subgroup analysis by AJCC stage

The association of diabetes status and diabetic treatments with overall survival among all CRC patients was significantly different depending on AJCC stage (**Table 3**, p for interaction <0.0001). Diabetic patients using metformin or other therapies had a significantly higher risk of death compared to non-diabetic patients in patients with Stage I-III CRC, but not among patients with Stage IV disease. In the subset of patients with diabetes, there was not a significant interaction between stage and diabetes treatment ($p=0.99$).

Diabetes treatments and OS: subgroup analysis by BMI and primary site

The protective association between use of metformin and overall survival among diabetics was not modified by BMI (p for interaction $=0.98$). Use of metformin was associated with improved survival in both normal weight ($HR_{adj}=0.77$, 95% CI 0.62-0.96, $p=0.02$) and overweight or obese subjects ($HR_{adj}=0.89$, 95% CI 0.80-0.99, $p=0.03$) (see Supplementary Table S1). There was no significant interaction between diabetes therapy and primary site (colon vs. rectum) ($p=0.43$, see Supplementary Table S2).

DISCUSSION

In an analysis of nearly 5000 patients with CRC and diabetes, we found that the use of metformin is associated with improved survival relative to patients treated with other therapies for their diabetes, even after adjustment for possible confounding by indication. This analysis presents the largest epidemiologic study of the association between metformin use and survival among patients with diabetes and CRC, and includes more patients than a recent meta-analysis aggregating data from individual studies (26). While it has been observed that diabetics with cancer have inferior outcomes compared to non-diabetics, the use of metformin is associated with a reduction in this survival disadvantage in the cohort of patients evaluated in this study. Diabetic patients taking metformin had only a 10% increase

in mortality rate relative to non-diabetic patients with colorectal cancer, as compared to a 22% increase for those diabetics treated with diabetic therapies other than metformin.

One potential biological mechanism linking diabetes and CRC includes the state of insulin resistance/hyperinsulinemia, which stimulates the IGFR pathway, and in turn may promote tumor cell proliferation and angiogenesis (31). Hyperglycemia itself and resulting oxidative stress, accumulation of advanced glycation end products, and chronic inflammation may enhance malignant transformation, cancer cell proliferation, metastasis, perineural invasion, and chemotherapy resistance, and inhibit apoptosis (32–35). Cancer has increased insulin–IGF-1 receptors, which may be associated with mitogenic signaling, and can be activated by insulin or insulin analogues (36,37). The use of insulin, compared to non-insulin antidiabetic drugs, has been associated with increased risk of CRC in a meta-analysis of epidemiologic studies.(38) There is less information on the role of the sulfonylurea family – drugs that block ATP-sensitive potassium channels in pancreatic beta cells to increase insulin release – on cancer cell growth, although there is some evidence that sulfonylurea receptors are associated with anti-tumor activity (39). Metformin acts through adenosine monophosphate-activated protein kinase (AMPK)/liver kinase B-1 (LKB1) pathway activation, but also inhibits the mammalian target of rapamycin (mTOR) and lowers IGF-1 levels, directly suppressing cell proliferation and indirectly reducing glucose and insulin levels (14,15). These effects are particularly intriguing for CRC because Peutz-Jeghers polyposis involves loss of LKB1, a tumor suppressor that also regulates AMPK. Metformin also appears to inhibit polyp formation and aberrant crypt foci (40–42).

Our results are concordant with several other epidemiologic investigations of the association between metformin use and survival among diabetic patients with CRC. Metformin use was significantly associated with lower overall- and CRC-specific mortality in a cohort of patients with type 2 diabetes (43). In an analysis of women enrolled in the Women's Health Initiative randomized trial, metformin use was associated with a 22% reduction in CRC-specific mortality after propensity score adjustment, although this finding was not statistically significant (22). However, a recent cohort study including 382 CRC deaths and adjusting for time-related biases failed to find any relation between metformin use and CRC survival (44). Evidence synthesis techniques have been used to address the challenge of low numbers of cases of CRC among diabetic patients by combining published epidemiologic studies on the metformin-survival association (26,45,46). Although these investigations also support a beneficial effect of metformin use on survival among CRC patients, inference from these studies is limited by significant between-study heterogeneity that remains unexplained, as well as typical challenges of meta-analysis of aggregated data, including non-standardized exposure and outcome definitions and heterogeneous approaches for confounding control. The present study overcomes many of these limitations due to the large database and comprehensive clinical detail available.

Although disease-specific survival would be the ideal outcome measure to understand the anti-cancer potential of metformin in this population, this information is not readily available in the VA database. Overall survival was the only endpoint available at the time of this analysis, so observed treatment differences could represent residual and unmeasured confounding by diabetes treatment indications and contraindications, or the beneficial effect

of improved glycemic control on diabetes-related complications and non-cancer death in users of metformin, rather than cancer-specific effects. However, our analyses are adjusted for a surrogate of glycemic control, HgA1c, as well as other variables related to diabetes status, including serum creatinine, body mass index, and other comorbidities. This allowed us to control for several possible mechanisms of confounding by indication and contraindication. Notably, the metformin treated group was similar to the non-metformin treated group with respect to HgA1c status and AJCC stage, while patients not receiving diabetic therapy may represent a relatively healthier user group, with a lower median HgA1c. Additionally, it is interesting that the strongest adjusted hazard ratio is observed in the population diagnosed with AJCC stage III CRC. This is a population that has greater potential survival benefit from a cancer-focused intervention compared to AJCC stage I or II disease, as the majority of patients with stage I and II disease are cured of their cancer with surgery. Survival of patients with AJCC stage IV CRC, on the other hand, appears less influenced by diabetes in general, regardless of treatment. This may speak to the biologic timeframe by which diabetes, as well as potential intervention with metformin, may impact cancer, or reflect underlying differences in metformin responsiveness between CRC presenting as stage III compared to stage IV.

This study is limited by a lack of detailed information on intensity of metformin treatment in terms of dosage and duration of use, and we did not evaluate diabetic therapy as a time-dependent exposure or have direct measures of compliance with dispensed drug. Nonetheless, the possible misspecification and misclassification of exposure is not expected to differ depending on survival outcomes, given the prospective capture of information in VA data systems and the relative homogeneity of health care access and quality among US veterans seeking cancer care within the VA system, so we expect misclassification to induce a bias towards the null that would underestimate the potential survival advantage associated with metformin use. The risk of time-related biases in pharmacoepidemiologic studies of metformin has received significant attention (47). While our approach to defining metformin exposure required documentation of two prescriptions, our investigation is less likely to be affected by this bias because our baseline was defined as cancer diagnosis (rather than prescription date), and exposure definitions were applied in the same way to both the metformin and the non-metformin treated group, the primary comparison group of interest.

This study advances our understanding of the association between metformin and improved survival in diabetic CRC patients and adds to a foundation of evidence supporting the anticancer effects of metformin. Unlike insulin and sulfonureas, metformin does not cause hypoglycemia in either patients with diabetes or normal subjects (48). Indeed, it has been used safely in polycystic ovary syndrome (49), non-alcoholic fatty liver disease (50), HIV lipodystrophy (51), and premature puberty (52). Several trials have been performed with metformin in non-diabetic patients with malignancies other than CRC with tolerable safety profile (53–59), while a combination of metformin with temsirolimus was not well tolerated (60). Metformin has been safely administered in a neoadjuvant CRC setting (61) and in combination with cytotoxic chemotherapy, including agents commonly used in CRC adjuvant settings (62), with a number of additional CRC studies underway. More definitive evidence of the potential clinical benefit of metformin in CRC will require evaluation using randomized controlled designs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Study funding: J.K. Paulus was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Numbers UL1TR000073 and UL1TR001064.

REFERENCES

1. American Cancer Society. Colorectal Cancer Facts & Figures 2014-2016. American Cancer Society; Atlanta: 2014.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010; 127:2893–917. [PubMed: 21351269]
3. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet*. 2011; 378:31–40. [PubMed: 21705069]
4. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. *Am J Epidemiol*. 2004; 159:1160–7. [PubMed: 15191933]
5. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, et al. Blood Glucose and Risk of Incident and Fatal Cancer in the Metabolic Syndrome and Cancer Project (Me-Can): Analysis of Six Prospective Cohorts. *PLoS Med*. 2009; 6:14.
6. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. *J Natl Cancer Inst*. 1999; 91:542–7. [PubMed: 10088625]
7. Giovannucci E. Insulin and colon cancer. *Cancer Causes Control*. 1995; 6:164–79. [PubMed: 7749056]
8. Geraldine, N.; Marc, A.; Carla, T.; Chantal, M.; Stefaan, B.; Welcome, W., et al. *Diabetes Res Clin Pract*. Vol. 97. Elsevier Ireland Ltd; 2012. Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting.; p. 331-6.
9. Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. *Dis Colon Rectum*. 2013; 56:1304–19. [PubMed: 24105007]
10. Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, et al. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. *J Natl Cancer Inst*. 2012; 104:1702–11. [PubMed: 23136358]
11. Campbell PT, Patel A V, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. *J Clin Oncol*. 2013; 31:876–85. [PubMed: 23341510]
12. Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B. Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: A case-control study. *Dig Dis Sci*. 2008; 53:2486–94. [PubMed: 18409001]
13. Giouleme O, Diamantidis MD, Katsaros MG. Is diabetes a causal agent for colorectal cancer? pathophysiological and molecular mechanisms. *World J Gastroenterol*. 2011:444–8. [PubMed: 21274373]
14. Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science*. 2005; 310:1642–6. [PubMed: 16308421]
15. Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAF V600E - driven melanoma by upregulating VEGF-A. *Cancer Discov*. 2012; 2:344–55. [PubMed: 22576211]
16. Hirsch HA, Iliopoulos D, Tschlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. *Cancer Res*. 2009; 69:7507–11. [PubMed: 19752085]

17. Zhang Y, Guan M, Zheng Z, Zhang Q, Gao F, Xue Y. Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. *PLoS One*. 2013;8.
18. Ruiter R, Visser LE, Van Herk-Sukel MPP, Coebergh JWW, Haak HR, Geelhoed-Duijvestijn PH, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. *Diabetes Care*. 2012; 35:119–24. [PubMed: 22100960]
19. Franciosi M, Lucisano G, Lapice E, Strippoli GFM, Pellegrini F, Nicolucci A. Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review. *PLoS One*. 2013;8.
20. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. *PLoS One*. 2012;7.
21. Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta- analysis. *Cancer Epidemiol Biomarkers Prev*. 2013; 22:2258–68. [PubMed: 24042261]
22. Cossor FI, Adams-Campbell LL, Chlebowski RT, Gunter MJ, Johnson K, Martell RE, et al. Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. *Cancer Epidemiol*. 2013; 37:742–9. [PubMed: 23773299]
23. Lee JH, Kim T II, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. *Int J Cancer*. 2011
24. Spillane S, Bennett K, Sharp L, Barron TI. A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. *Cancer Epidemiol Biomarkers Prev*. 2013; 22:1364–73. [PubMed: 23753040]
25. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. *Br J Cancer*. 2012; 106:1374–8. [PubMed: 22421948]
26. Mei Z-B, Zhang Z-J, Liu C-Y, Liu Y, Cui A, Liang Z-L, et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta- analysis. *PLoS One*. 2014; 9:e91818. [PubMed: 24647047]
27. Zullig LL, Jackson GL, Dorn RA, Provenzale DT, McNeil R, Thomas CM, et al. Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. *Mil Med*. 2012; 177:693–701. [PubMed: 22730846]
28. Sohn M-W, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. *Popul Health Metr*. 2006; 4:2. [PubMed: 16606453]
29. Greene, FL.; Page, DL.; Fleming, ID. *AJCC Cancer Staging Manual*. 6th ed.. Springer-Verlag; New York: 2002.
30. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987; 40:373–83. [PubMed: 3558716]
31. Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. *Nat Clin Pract Oncol*. 2005; 2:48–53. [PubMed: 16264856]
32. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. *Ann Transl Med*. 2014; 2:57. [PubMed: 25333032]
33. Kulkarni MJ, Korwar AM, Mary S, Bhonsle HS, Giri AP. Glycated proteome: From reaction to intervention. *Proteomics - Clin. Appl*. 2013:155–70. [PubMed: 23184864]
34. Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression. *Diabetes Metab J*. 2014; 38:330–6. [PubMed: 25349819]
35. Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R, et al. Hyperglycemia, a neglected factor during cancer progression. *Biomed Res. Int*. 2014
36. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. *Endocr. Rev*. 2007:20–47. [PubMed: 16931767]
37. Janssen JAMJL, Varewijck AJ. IGF-IR Targeted Therapy: Past, Present and Future. *Front Endocrinol (Lausanne)*. 2014; 5:224. [PubMed: 25566194]
38. Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of insulin and insulin analogs and risk of cancer - systematic review and meta- analysis of observational studies. *Curr Drug Saf*. 2013; 8:333–48. [PubMed: 24215311]

39. Pasello G, Urso L, Conte P, Favaretto A. Effects of sulfonylureas on tumor growth: a review of the literature. *Oncologist*. 2013; 18:1118–25. [PubMed: 24043597]
40. Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. *BMC Cancer*. 2012;118. [PubMed: 22443173]
41. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. *Cancer Prev Res*. 2010; 3:1077–83.
42. Cho YH, Ko BM, Kim SH, Myung YS, Choi JH, Han JP, et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? *Intest Res*. 2014; 12:139–45. [PubMed: 25349581]
43. Lee JH, Kim T Il, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. *Int J Cancer* [Internet]. 2012; 131:752–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21913184>.
44. Mc Menamin ÚC, Murray LJ, Hughes CM, Cardwell CR. Metformin use and survival after colorectal cancer: A population-based cohort study. *Int J cancer*. 2016; 138:369–79. [PubMed: 26331456]
45. Zhang Z-J, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab*. 2014
46. He X-K, Su T-T, Si J-M, Sun L-M. Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta- Analysis. *Medicine (Baltimore)*. 2016; 95:e2749. [PubMed: 26886616]
47. Suissa S, Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. *Diabetes Care*. 2012;2665–73. [PubMed: 23173135]
48. [2015 Jan 1] Glucophage (metformin hydrochloride tablets).. Drugs@FDA [Internet]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf
49. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. *BMJ*. 2003; 327:951–3. [PubMed: 14576245]
50. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. *Exp. Diabetes Res*. 2012
51. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. *JAMA*. 2000
52. Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Pubertal Metformin Therapy to Reduce Total, Visceral, and Hepatic Adiposity. *J Pediatr*. 2010;156.
53. Laskov I, Drudi L, Beauchamp M-C, Yasmeen A, Ferenczy A, Pollak M, et al. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. *Gynecol Oncol*. 2014; 134:607–14. [PubMed: 24972190]
54. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, et al. Phase i trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. *Cancer Chemother Pharmacol*. 2013; 71:63–72. [PubMed: 23053261]
55. Campagnoli C, Pasanisi P, Abbà C, Ambroggio S, Biglia N, Brucato T, et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: A randomized study. *Clin Breast Cancer*. 2012; 12:175–82. [PubMed: 22607767]
56. Kalinsky, K.; Crew, KD.; Refice, S.; Xiao, T.; Wang, A.; Feldman, SM., et al. *Cancer Invest*. Vol. 32. England: 2014. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.; p. 150–7.
57. Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. *Br J Cancer*. 2013; 109:2792–7. [PubMed: 24157825]
58. Niraula S, Dowling RJO, Ennis M, Chang MC, Done SJ, Hood N, et al. Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. *Breast Cancer Res. Treat*. 2012;821–30. [PubMed: 22933030]

59. Kim J, Lim W, Kim E-K, Kim M-K, Paik N-S, Jeong S-S, et al. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). *BMC Cancer*. 2014; 14:170. [PubMed: 24612502]
60. MacKenzie MJ, Ernst S, Johnson C, Winqvist E. A phase I study of temsirolimus and metformin in advanced solid tumours. *Invest New Drugs*. 2012; 30:647–52. [PubMed: 20978924]
61. DeVito NC, Goodman MD, Caplain J, Rajagopal S, Daniel Popowich D, Orkin B, et al. A pilot study evaluating the safety and impact of pretreatment with metformin on colorectal cancer stem cells (CCSC) in patients undergoing resection. *J Clin Oncol*. 2014:32.
62. Kritharis A, Caplain J, Rajagopal S, Grimm E, Tschlis PN, Martell R, et al. A phase I study of metformin and chemotherapy in solid tumors. *J Clin Oncol*. 2014; 32(suppl) abstract 2560.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Demographic and treatment characteristics of colorectal cancer cases by diabetes and diabetes treatment status

	Non-Diabetic cases N=16309	Diabetic cases		
		Metformin N=2,033	Non-Metformin treatment N=2,132	No diabetic treatment N=818
Age at diagnosis (years)				
Median	68.6	67.9	73.3	72.6
IQR	17.1	14.0	14.3	14.5
Age category, no. (%)				
<65	6731 (41.3)	821 (40.4)	519 (24.3)	209 (25.5)
65	9578 (58.7)	1212 (59.6)	1613 (75.7)	609 (74.4)
Race, no. (%)				
Black	2777 (17.0)	285 (14.0)	438 (20.5)	160 (19.6)
White	13113 (80.4)	1689 (83.1)	1633 (76.6)	644 (78.6)
Other	161 (1.0)	21 (1.0)	33 (1.5)	9 (1.1)
Unknown	258 (1.6)	38 (1.9)	28 (1.3)	5 (0.7)
BMI (kg/m ²)				
Median	26.6	30.4	29.0	28.3
IQR	6.8	7.8	7.3	7.1
Category, %				
Underweight (<18.5)	492 (3.0)	11 (0.5)	26 (1.2)	11 (1.3)
Normal (18.5-24.9)	4942 (30.3)	284 (14.0)	387 (18.1)	186 (22.7)
Overweight (25.0-29.9)	5555 (34.1)	659 (32.4)	774 (36.3)	291 (35.6)
Obese (≥ 30)	4019 (24.6)	1066 (52.4)	924 (43.3)	304 (37.3)
Missing	1301 (8.0)	13 (0.6)	21 (1.0)	26 (3.2)
Smoking status, no. (%)				
Never smoked	3494 (21.4)	533 (26.2)	539 (25.3)	232 (28.4)
Current smoker	4713 (28.9)	408 (20.1)	387 (18.1)	156 (19.1)
Former smoker	5866 (36.0)	833 (41.0)	883 (41.4)	299 (36.5)
Missing	2236 (13.7)	259 (12.7)	323 (15.1)	131 (16.0)
AJCC Cancer stage, no. (%)				
I	4289 (26.3)	635 (31.2)	605 (28.4)	246 (30.1)
II	4394 (26.9)	559 (27.5)	611 (28.7)	203 (24.8)
III	4017 (24.6)	509 (25.0)	540 (25.3)	186 (22.7)
IV	3609 (22.1)	330 (16.2)	376 (17.6)	183 (22.4)
Comorbidities, no. (%) ^a				
0	7764 (47.6)	905 (44.5)	618 (29.0)	262 (32.0)
1-3	7229 (44.3)	942 (46.3)	1114 (52.2)	441 (54.1)

	Non-Diabetic cases N=16309	Diabetic cases		
		Metformin N=2,033	Non-Metformin treatment N=2,132	No diabetic treatment N=818
>=4	1316 (8.1)	186 (9.2)	400 (18.7)	115 (14.0)
Cardiovascular disease ^b , no. (%)	10123 (62.1)	1812 (89.1)	1943 (91.1)	720 (88.0)
Lab values	-----			
Creatinine (mg/dL)				
Median		1.0	1.2	1.1
IQR		0.3	0.5	0.4
Category, %				
<1.1		1074 (52.8)	681 (31.9)	373 (45.6)
>=1.1		887 (43.6)	1373 (64.4)	406 (49.6)
Missing(%)		72 (3.5)	78 (3.7)	39 (4.8)
HbA1c (%)				
Median		6.9	6.8	6.2
IQR		1.5	1.5	1.2
Category, %				
<6.8		734 (36.1)	875 (41.0)	440 (53.7)
>=6.8		1041 (51.2)	960 (45.0)	182 (22.2)
Missing		258 (12.7)	297 (14.0)	196 (24.0)
Median survival time (mos), (IQR)	62.6 (86.0)	75.4 (73.3)	45.1 (81.1)	49.9 (88.1)
5-year overall survival, N(%)	7974 (48.9)	1107 (54.4)	837 (39.3)	344 (42.0)
Sex, no. (%)				
Female	341 (2.1)	33 (1.6)	27 (1.3)	15 (1.8)
Male	15968 (97.9)	2000 (98.4)	2105 (98.7)	803 (98.2)
Cancer treatment, no. (%)				
None	1800 (11.0)	158 (7.7)	232 (11.0)	137 (16.8)
Surgery only	7868 (48.2)	1088 (53.5)	1219 (57.2)	448 (54.6)
Surgery + RT	347 (2.1)	31 (1.5)	25 (1.2)	19 (2.3)
Surgery + CT	3224 (19.8)	426 (20.9)	378 (17.7)	121 (14.9)
Surgery + RT + CT	1200 (7.3)	142 (7.0)	101 (4.7)	28 (3.4)
RT	275 (1.7)	25 (1.2)	22 (1.0)	15 (1.8)
CT	835 (5.1)	90 (4.5)	79 (3.7)	32 (4.0)
CT + RT	760 (4.6)	73 (3.6)	76 (3.6)	18 (2.2)
Primary Site				
Colon ^c	12380 (75.9)	1654 (81.4)	1742 (81.7)	676 (82.6)
Rectum	3929 (24.1)	379 (18.6)	390 (18.3)	142 (17.4)

^aBased on Charlson comorbidity index

^bBased on ICD-9 codes for coronary heart disease, stroke, cardiovascular disease, hypertension, heart failure

^cIncludes colon, cecum, rectosigmoid junction

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Diabetes treatment and overall survival in Cox proportional hazards models in patients with colorectal cancer

Table 2

All patients (N=21,292)						Diabetic patients (N=4,983)				
Diabetes Therapy	N deaths/total N	Unadj HR (95% CI)	p-value	AHR ^a (95% CI)	p-value	Diabetes Therapy	Unadj HR (95% CI)	p-value	AHR ^b (95% CI)	p-value
No diabetes	10,647/16,309	1.00	ref	1.00	ref	Non-Metformin	1.00	ref	1.00	ref
Metformin	1,282/2,033	0.92 (0.87-0.97)	0.004	1.10 (1.03-1.17)	0.004	Metformin	0.70 (0.65-0.76)	<0.0001	0.87 (0.79-0.95)	0.003
Non-Metformin	1,591/2,132	1.30 (1.23-1.37)	<0.0001	1.22 (1.15-1.29)	<0.0001	None	0.94 (0.85-1.03)	0.17	1.02 (0.90-1.15)	0.76
None	607/818	1.22 (1.13-1.33)	<0.0001	1.16 (1.06-1.27)	0.002					

^a Adjusted for age (years), race (black, white, other, unknown), AJCC stage (I, II, III, IV), BMI (kg/m²), comorbidity index (number), CRC treatment (none, surgery only, surgery+RT, surgery+CT, surgery+RT+CT RT, CT, CT+RT), smoking status (current, former, never, missing)

^b Adjusted for age (years), race (black, white, other, unknown), AJCC stage (I, II, III, IV), BMI (kg/m²), comorbidity index (number), CRC treatment (none, surgery only, surgery+RT, surgery+CT, surgery+RT+CT RT, CT, CT+RT, smoking status (current, former, never, missing), HgA1c (%), creatinine (mg/dL)

Diabetes treatment and overall survival in Cox proportional hazards models in patients with colorectal cancer, BY STAGE

Table 3

All patients, STAGE I (N=5775) ^a						Diabetic patients, STAGE I (N=1486) ^b					
Diabetes Therapy	N deaths/total N	Unadj HR (95% CI)	p-value	AHR ^c (95% CI)	p-value ^c	Diabetes Therapy	Unadj HR (95% CI)	p-value	AHR ^d (95% CI)	p-value ^d	
No diabetes	2167/4289	1.00	ref	1.00	ref	Non-Metformin	1.00	ref	1.00	ref	
Metformin	324/635	1.05 (0.94-1.18)	0.39	1.28 (1.13-1.46)	0.0002	Metformin	0.64 (0.56-0.75)	<0.0001	0.91 (0.76-1.10)	0.35	
Non-Metformin	401/605	1.63 (1.47-1.81)	<0.0001	1.33 (1.17-1.50)	<0.0001	None	0.85 (0.70-1.02)	0.0806	0.93 (0.72-1.19)	0.55	
None	154/246	1.39 (1.18-1.64)	<0.0001	1.13 (0.94-1.36)	0.20						

All patients, STAGE II (N=5767)						Diabetic patients, STAGE II (N=1373)					
Diabetes Therapy	N deaths/total N	Unadj HR (95% CI)	p-value	AHR ^c (95% CI)	p-value ^c	Diabetes Therapy	Unadj HR (95% CI)	p-value	AHR ^d (95% CI)	p-value ^d	
No diabetes	2638/4394	1.00	ref	1.00	ref	Non-Metformin	1.00	ref	1.00	ref	
Metformin	337/559	0.98 (0.88-1.10)	0.76	1.16 (1.02-1.31)	0.0235	Metformin	0.67 (0.58-0.78)	<0.0001	0.87 (0.73-1.04)	0.13	
Non-Metformin	443/611	1.45 (1.31-1.61)	<0.0001	1.36 (1.21-1.52)	<0.0001	None	0.87 (0.72-1.05)	0.15	1.03 (0.80-1.32)	0.84	
None	147/203	1.27 (1.10-1.50)	0.0044	1.14 (0.94-1.38)	0.18						

All patients, STAGE III (N=5252)						Diabetic patients, STAGE III (N=1235)					
Diabetes Therapy	N deaths/total N	Unadj HR (95% CI)	p-value	AHR ^c (95% CI)	p-value ^c	Diabetes Therapy	Unadj HR (95% CI)	p-value	AHR ^d (95% CI)	p-value ^d	
No diabetes	2509/4017	1.00	ref	1.00	ref	Non-Metformin	1.00	ref	1.00	ref	
Metformin	319/509	1.00 (0.89-1.12)	0.98	1.17 (1.03-1.33)	0.0171	Metformin	0.71 (0.61-0.83)	<0.0001	0.84 (0.70-1.00)	0.05	
Non-Metformin	398/540	1.40 (1.26-1.56)	<0.0001	1.33 (1.18-1.50)	<0.0001	None	0.87 (0.72-1.06)	0.18	0.97 (0.76-1.25)	0.82	
None	136/186	1.22 (1.03-1.45)	0.024	1.14 (0.94-1.38)	0.17						

All patients, STAGE IV (N=4498)						Diabetic patients, STAGE IV (N=889)					
Diabetes Therapy	N deaths/total N	Unadj HR (95% CI)	p-value	AHR ^c (95% CI)	p-value ^c	Diabetes Therapy	Unadj HR (95% CI)	p-value	AHR ^d (95% CI)	p-value ^d	
No diabetes	3333/3609	1.00	ref	1.00	ref	Non-Metformin	1.00	ref	1.00	ref	
Metformin	302/330	0.91 (0.81-1.02)	0.12	0.96 (0.84-1.10)	0.56	Metformin	0.79 (0.68-0.92)	0.0026	0.89 (0.73-1.08)	0.23	
Non-Metformin	349/379	1.17 (1.04-1.30)	0.007	1.05 (0.93-1.19)	0.42	None	1.09 (0.91-1.31)	0.34	1.10 (0.87-1.42)	0.40	

All patients, STAGE IV (N=4498)						Diabetic patients, STAGE IV (N=889)				
Diabetes Therapy	N deaths/total N	Unadj HR (95% CI)	p-value	AHR ^c (95% CI)	p-value ^c	Diabetes Therapy	Unadj HR (95% CI)	p-value	AHR ^d (95% CI)	p-value ^d
None	170/183	1.28 (1.10-1.49)	0.002	1.20 (1.01-1.43)	0.04					

^aWald p-value for metformin status*stage interaction term (adjusted for age, race, BMI, comorbidity, CRC treatment) among **all patients**: <0.0001

^bWald p-value for metformin status*stage interaction term (adjusted for age, race, BMI, comorbidity, CRC treatment, HgA1c, creatinine) among **diabetic patients**: 0.99

^cAdjusted for age, race, BMI, comorbidity index, CRC treatment, smoking status

^dAdjusted for age, race, BMI, comorbidity index, CRC treatment, smoking status, HgA1c, creatinine